531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

₹17.51 -0.92 (-4.99%)

04 Mar, 2025 10:57

SIP TrendupStart SIP in VENMAX

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -37.93%
  • Over 3 Month + 340.91%
  • Over 6 Month + 340.91%
  • Over 1 Year + 340.91%
SIP Lightning

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹17.51
-0.92 (-4.99%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹23.79
  • 50 Day
  • ₹21.96
  • 100 Day
  • ₹17.05
  • 200 Day
  • ₹12.11

Resistance and Support

18.43 Pivot Speed
  • R3 18.43
  • R2 18.43
  • R1 18.43
  • S1 18.43
  • S2 18.43
  • S3 18.43

What's your outlook on Venmax Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 0.57 Cr. on a trailing 12-month basis. An annual revenue de-growth of -52% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -9% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 99 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 71 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-08 Quarterly Results
2025-01-11 Preferential issue of shares
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-14 Audited Results

Venmax Drugs & Pharmaceuticals F&O

Venmax Drugs & Pharmaceuticals Shareholding Pattern

23.13%
0.15%
65.54%
11.18%

About Venmax Drugs & Pharmaceuticals

  • NSE Symbol
  • VENMAX
  • BSE Symbol
  • 531015
  • Managing Director
  • Mr. N Krishnaiah
  • ISIN
  • INE154G01022

Similar Stocks to Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹17 As on 04 March, 2025 | 10:43

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹9.2 Cr As on 04 March, 2025 | 10:43

The P/E ratio of Venmax Drugs & Pharmaceuticals is -12.3 As on 04 March, 2025 | 10:43

The PB ratio of Venmax Drugs & Pharmaceuticals is -14.1 As on 04 March, 2025 | 10:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23